

9ème journée CRIOAc Lyon – Mardi 27 juin 2023

Phagothérapie dans les IOA: protocole PhagoDAIR I

Pr. Tristan Ferry, MD, PhD

tristan.ferry@univ-lyon1.fr

 @FerryLyon 

Infectious and Tropical Diseases Unit, Croix-Rousse Hospital , Hospices Civils de Lyon, Claude Bernard Lyon1 University, Lyon
Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France

Clinical officer ESCMID Study group for Non-Traditional Antibacterial therapy (ESGNTA)

Centre de Référence des IOA complexes de Lyon (CRIOAc Lyon)




Bacteria have also their pandemia!



World Health Organization

Non-**T**raditional
Antibacterial
therapy



PHAGE*in***LYON**
Clinic

 **ESGNTA**
European Society of Clinical Microbiology and Infectious Diseases

ESCMID STUDY GROUP
FOR NON-TRADITIONAL
ANTIBACTERIAL THERAPY


Merabishvili et al. *Plos ONE* 2009

Bacteria have also their pandemia!



World Health Organization

**Non-Traditional
Antibacterial
therapy**



ESGNTA
European Society of Clinical Microbiology and Infectious Diseases

ESCMID STUDY GROUP
FOR NON-TRADITIONAL
ANTIBACTERIAL THERAPY


FONDATION
HCL
HOSPISES CIVILS
DE LYON

PHAGEinLYON
Clinic

T. Ferry. Springer 2023 In press

Phagothérapie dans les IOA : le programme PHAGEinLYON Clinic

Implementation of a Phage Therapy Center in a CRIODAc



55 patients in Lyon since 2017

~80% of the whole patients treated in France



- 51 with phages from PHERECDYES PHARMA
- 4 with phages from MHKA HMRA
- 43 **BJI** (including **35 PJI**)
- 9 **endocarditis/vascular graft**
- 3 **lung infections** (VAP + bacteremia, pneumonia in lung graft bronchectasia, cystic fibrosis exacerbation)

+ 13 patients managed outside Lyon including 1 in and 1 in


BJI

Endocarditis

Pneumonia

Cohort A (before 2019)


6 patients received 1-shot of active phages during open (n=4) or arthroscopic (n=2) DAIR



PHAGE*in*LYON
Clinic




Cohort A (before 2019)



6 patients received **1-shot** of active phages
during open (n=4) or arthroscopic (n=2) DAIR

PHAGEinLYON
Clinic

#PhagoDAIR
procedure




PHAGEinLYON
Clinic




Cohort A (before 2019)

6 patients received 1-shot of active phages during open (n=4) or arthroscopic (n=2) DAIR



Cohort A (before 2019)




2 experienced
a relapse under SAT
>>2 years later



6 patients received 1-shot of active phages
during open (n=4) or arthroscopic (n=2) DAIR



Cohort A (before 2019)





Phagothérapie dans les IOA : l'essai thérapeutique PhagoDAIR I

Promotion Phaxiam (Ex Pherecydes)

PhagoDAIR I


A Pilot, Multicenter, Randomized, Non-Comparative, Double-Blind Study of
Phage Therapy in Patients with Hip or Knee PJI due to *S. aureus*
Treated with DAIR and Antibiotic Therapy

Inclusion Criteria

1. *S. aureus* monomicrobial knee or hip PJI with clinical signs of infection with indication of DAIR and **Suppressive Antibiotics Therapy (SAT)**.
2. Phagogram displaying the susceptibility of the strain to at least one of the anti-*Staphylococcus aureus* bacteriophages

Primary Objective

To estimate the **rate of clinical control of infection at Week 12±2** which will allow to calculate the sample size for future comparative studies.




Phagothérapie dans les IOA : l'essai thérapeutique PhagoDAIR I

Promotion Phaxiam (Ex Pherecydes)

PhagoDAIR I

A Pilot, Multicenter, Randomized, Non-Comparative, Double-Blind Study of
Phage Therapy in Patients with Hip or Knee PJI due to *S. aureus*
Treated with DAIR and Antibiotic Therapy

Study design



Phagothérapie dans les IOA : l'essai thérapeutique PhagoDAIR I

Promotion Phaxiam (Ex Pherecydes)

Bras	Voie D'administration	Plan d'administration	Traitement de Référence + + Antibiothérapie suppressive (SAT) (voie orale)
Contrôle (n=30)	Injection intra articulaire après le DAIR	D0: DAIR + 30 ml de solution NaCl 0.9% à la fin de la procédure chir OU D0: 5ml de solution NaCl 0.9% 14±2j après le DAIR par injection intra articulaire echoguidée	Au total 12 semaines d'antibiothérapie curative, avec 5 à 15 jours d'administration IV, puis voie orale et en incluant la rifampicine selon les antécédents cliniques du patient, les contre- indications, les interactions médicamenteuses, l'antibiogramme et les recommandations.. +
Phages (n=30)		D0: DAIR + bacteriophages* actifs dilués dans NaCl 0.9% pour un volume total de 30 ml à la fin de la procédure chir OU D0: bacteriophages* actifs dilués dans NaCl 0.9% pour un volume de 5ml à 14±2j après le DAIR par injection intra articulaire echoguidée	SAT après 12 semaines d'antibiothérapie curative selon les antécédents cliniques du patient, les contre-indications, les interactions médicamenteuses, l'antibiogramme et les recommandations : cefalexine, cotrimoxazole, cyclines (minocycline ou doxycycline) Cette liste n'est pas exhaustive.

Clinical case

76-year-old man

Bladder cancer, Diabetes

Heart failure, arythmia

Chronic kidney injury

Mesenteric ischaemia

Left hip prosthesis, 1-stage exchange



PHAGE*in***LYON**
Clinic



Clinical case

76-year-old man


Bladder cancer, Diabetes

Heart failure, arythmia

Chronic kidney injury

Mesenteric ischaemia

Left hip prosthesis, 1-stage exchange



PHAGE*in***LYON**
Clinic



Clinical case

76-year-old man

Bladder cancer, Diabetes

Heart failure, arythmia

Chronic kidney injury

Mesenteric ischaemia

Left hip prosthesis, 1-stage exchange

Failure followed by DAIR and SAT

Iterative failure due to *S. aureus*


Severe pain, Bedridden



PHAGE*in***LYON**
Clinic



Clinical case




Courtesy C. FOISSEY




PHAGE*in***LYON**
Clinic



Clinical case



Clinical case



Clinical case



PHAGE*in*LYON
Clinic

Clinical case

54-year-old woman

Bilateral prosthetic knee infection

Due to *S. aureus*

1-stage exchange for the right

PhagoDAIR I for the left

Severe pain, flessum



Bedridden



PHAGE*in***LYON**
Clinic



Clinical case



HCL
HOPITAUX CIVILS
DE LYON

UFB
Lyon 1

PHAGE*in*LYON
Clinic

ciri
Centre International de Recherche en Infectiologie

FONDATION
HCL
HOPITAUX CIVILS
DE LYON



PHAGE*in***LYON**
Clinic

ciri
Centre
International
de Recherche
en Infectiologie

FONDATION
HCL
HOSPISES CIVILS
DE LYON

Clinical case



PHAGE *in* LYON
Clinic

Phagothérapie dans les IOA : l'essai thérapeutique PhagoDAIR I

Promotion Phaxiam (Ex Pherecydes)

RECRUTEMENT FRANCE

CRIOAc	Investigateur Principal	Recrutement	Administration Phages/Placebo	Rechute	Sortie d'étude
LYON	Pr Ferry	8	7 (Fin du DAIR) 1 (DAIR + 14j)	1	1
TOURCOING	Pr Senneville	1	Fin du DAIR	0	0
RENNES	Dr Patrat-Delon	1	Fin du DAIR	0	1
NIMES	Pr Sotto	1	DAIR + 14j	0	0
BORDEAUX	Dr Dauchy	1	DAIR + 14j	0	0
POITIERS	Dr Le Moal	1	DAIR + 14j	0	0
BREST	Pr Ansart	1	Fin du DAIR	0	0
TOURS	Dr Lacasse	1	Fin du DAIR	0	0

LE PROGRÈS

News ▾ Departments ▾ Sport ▾ Long format ▾ Culture - Leisure ▾ Magazine ▾ Services ▾ Q

► Infections ostéo-articulaires : Lyon devient le centre expert national pour la phagothérapie

Essai PhagoDAIR I

s complexes,
s, utilisant

Essai CF-301-108


Le Progrès - 23 févr. 2023 à 17:51 | mis à jour le 23 févr. 2023 à 18:08 - Temps de lecture : 2 min



RCP CRIOAc
Thérapie innovante



HCR.REFERENCE-IOA@chu-lyon.fr




Fraternité

Dédiée aux thérapies
non traditionnelles (OMS)



<http://www.crioac-lyon.fr>



- Published cases
- Open acces studies in pdf
- All thesis in pdf
- All recommendations
- Newsletter



PHAGE*in*LYON
Clinic



@ Tristan Ferry

@ FerryLyon

@ CRIODClyon

Channel

